Merck & Co. Stock News

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, patritumab deruxtecan (HER3-DXd) based on the HERTHENA-Lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-...

Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performance pleasantly surprised me in Q1 2025, and thanks to which Merck's operating income margin remains above 40%, are Vaxneuvance, Winrevair, and Welireg. From its oncology franchise, I highlight Weli...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2025 Dividend.

Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.

The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approv...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare ...

Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially Keytruda—drives strong segment performance, offsetting declines in virology and diabetes products. Management is aggressively investing in R&D and manufacturing expansion, with a robust drug pipelin...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.